title: Monoclonal antibody therapy in sinonasal disease.
abstract: Chronic rhinosinusitis (CRS) affects 12.5% of the U.S.
  
  
  METHODS
  CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E (omalizumab), anti-interleukin 5 (mepolizumab and reslizumab), and anti-interleukin 4/interleukin 13 (dupilumab) monoclonal antibodies for the treatment of CRSwNP. In addition, we discussed the importance of some of these clinical trials in identifying new CRS endotypes based on distinct inflammatory profiles.
authors.affiliation: Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
authors.forename: Sergio E
authors.initials: SE
authors.lastname: Chiarella
authors.forename: Hendrik
authors.initials: H
authors.lastname: Sy
authors.forename: Anju T
authors.initials: AT
authors.lastname: Peters
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002908:Chronic Disease; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000276:immunology; D015848:Interleukin-5 / Q000276:immunology; D009298:Nasal Polyps / Q000276:immunology*; D000069444:Omalizumab / Q000627:therapeutic use; D012220:Rhinitis / Q000276:immunology*; D012852:Sinusitis / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018793:Interleukin-13; D015848:Interleukin-5; D015847:Interleukin-4; D000069444:Omalizumab; C515492:reslizumab; D007073:Immunoglobulin E; C582203:dupilumab; C434107:mepolizumab